FDA finds no misconduct by Care Access in Pfizer’s Lyme vaccine trial
Care Access announced today the completion of a for-cause Food and Drug Administration ("FDA") Good Clinical Practices ("GCP") inspection related to Care Access's activities on the Pfizer VALOR trial. The inspection resulted in no FDA Form 483 observations...
Read More